PMC:7228307 / 52334-52502 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1044","span":{"begin":74,"end":78},"obj":"Gene"},{"id":"1049","span":{"begin":132,"end":142},"obj":"Chemical"},{"id":"1050","span":{"begin":147,"end":157},"obj":"Chemical"}],"attributes":[{"id":"A1044","pred":"tao:has_database_id","subj":"1044","obj":"Gene:2213"},{"id":"A1049","pred":"tao:has_database_id","subj":"1049","obj":"MESH:C502540"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T885","span":{"begin":74,"end":76},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4)."}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1044","span":{"begin":74,"end":78},"obj":"Gene"},{"id":"1049","span":{"begin":132,"end":142},"obj":"Chemical"},{"id":"1050","span":{"begin":147,"end":157},"obj":"Chemical"}],"attributes":[{"id":"A1044","pred":"pubann:denotes","subj":"1044","obj":"Gene:2213"},{"id":"A1049","pred":"pubann:denotes","subj":"1049","obj":"MESH:C502540"}],"text":"It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4)."}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T298","span":{"begin":0,"end":168},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T298","span":{"begin":0,"end":168},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"It is often referred to as the “LALA mutation” and effectively eliminates FcγR binding by more than 100 fold104, 105 and is used in teplizumab and spesolimab (Table 4)."}